CLINICAL TRIALS PROFILE FOR HYDROGEN PEROXIDE
✉ Email this page to a colleague
All Clinical Trials for HYDROGEN PEROXIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Development Center for Biotechnology, Taiwan | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Program Office, National Science & Technology, Biotechnology & Pharmaceuticals | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| NCT00154635 ↗ | Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease | Unknown status | Taipei Veterans General Hospital, Taiwan | Phase 2 | 2005-09-01 | A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROGEN PEROXIDE
Condition Name
Clinical Trial Locations for HYDROGEN PEROXIDE
Trials by Country
Clinical Trial Progress for HYDROGEN PEROXIDE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROGEN PEROXIDE
Sponsor Name
